Lysogene Announces Company Presentations at October & November Investor Conferences

Wednesday, October 4, 2017 8:00 AM UTC

PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:

October

Chardan Gene Therapy Conference (New York, US)
	Date:	Wednesday, October 11
	Time	3:45pm Eastern Time
	Location:	Westin New York Grand Central, Assembly Room

Jefferies Gene Editing & Gene Therapy Summit (New York, US)
	Date:	Thursday, October 12
	Time:	2:30pm Eastern Time
	Location:	Westin New York Grand Central

Key Opinion Leader Lunch: Gene Therapy for Patients with Sanfilippo Syndrome Type A (MPS IIIA) (New York, US)
	Date:	Friday, October 13
	Time:	12:00pm – 1:30pm Eastern Time
	Location	Lotte New York Palace Hotel

Webcast: http://lifesci.rampard.com/20171013/reg.jsp

November

Jefferies 2017 London Healthcare Conference (London, UK)
	Date:	Tuesday, November 14 & Wednesday, November 15
	Time:	TBD
	Location	Waldorf Hilton

About Lysogene

Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.

Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).

For more information: www.lysogene.com.

Contacts

Media:		Investors:

Europe
Annie-Florence Loyer		Chris Maggos
NewCap		LifeSci Advisors
[email protected]		[email protected]
+ 33 6 88 20 35 59		+41 79 367 6254
+ 33 1 44 71 00 12

North America
Marion Janic
RooneyPartners
[email protected]
+ 1 (212) 223-4017

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Lysogene Announces Company Presentations at October & November Investor Conferences

Editor's Picks

Welcome to EconoTimes